Merck buys AI drug designs from Isomorphic Labs two days after its $5 billion round
MSD, Merck & Co. (NYSE: MRK) outside the United States and Canada, carries the clinical and commercial risk and pays an undisclosed upfront, milestones and tiered royalties, while Isomorphic Labs holds a new option to co-fund trials for elevated royalties. Two days after the largest life-science venture round ever, the deal hands Alphabet's (Nasdaq: GOOGL) AI drug spinout its fourth Big Pharma payer before any candidate has entered a human trial.
Vincent Jiangthree-minute read
Merck buys designs for an unnamed cancer target
On November 19, Isomorphic Labs$600M — Isomorphic Labs, private, latest valuation $600M, the Google DeepMind spinout led by founder and chief executive Demis Hassabis, winner of the 2024 Nobel Prize in Chemistry for AlphaFold, agreed to discover small-molecule candidates against an oncology target neither company will name, together with MSD, Merck & Co.'s−3.66% — Merck & Co., down 3.66 percent today (NYSE: MRK) trade name outside the United States and Canada 12. Isomorphic runs its IsoDDE drug-design engine over MSD's proprietary data sets and hands back molecular designs; MSD owns everything downstream: preclinical and clinical development, manufacturing and sales 1.
The clinic stays Merck's risk
Money flows toward the lab. Isomorphic takes an undisclosed upfront payment, then research, development, regulatory and commercial milestones, then tiered royalties on net sales 1. The term that carries the story is an option for Isomorphic to co-fund development in return for elevated royalties, noted in passing across the deal's coverage 13. George Addona, who heads discovery, preclinical development and translational medicine at MSD Research Laboratories, cast the pairing as "close coordination of wet-lab and dry-lab functions" 1. Isomorphic sells the designs; Merck buys the risk.
$7.7 billion raised, no valuation given
The option now has a balance sheet behind it. On November 17 Isomorphic closed an oversubscribed $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining and Alphabet−3.40% — Alphabet, down 3.40 percent today (Nasdaq: GOOGL) investing significantly; the UK BioIndustry Association called it the largest life-science venture raise ever 456.
The money is earmarked for foundational models, the pipeline and clinical-development infrastructure 5. Disclosed funding now stands at $7.7 billion, after $600 million in March 2025 and a $2.1 billion Series B in May 2. The valuation went unsaid; Bloomberg reported a $50 billion ask, on top of the $40 billion or more The Inference reported on October 9 478.
Isomorphic's funding has grown from $0.6 billion to $5 billion a round in 20 months
Each round dwarfed the last, and still no candidate in a human trial
Data
| Raised | |
|---|---|
| Mar 2025 | $0.6bn |
| May 2026 | $2.1bn |
| Nov 2026 | $5bn |
Four of the top eight drugmakers, zero human trials
Merck is the fourth Big Pharma name on the roster, after Eli Lilly−2.19% — Eli Lilly, down 2.19 percent today and Novartis−2.57% — Novartis, down 2.57 percent today signed 2024 alliances worth about $3 billion combined including milestones and Johnson & Johnson−2.09% — Johnson & Johnson, down 2.09 percent today followed this year, a partner list spanning four of the top eight drugmakers by revenue 910. No Isomorphic candidate has entered a human trial; its oncology and immunology results are described only as "positive preclinical", with no named first candidate and no clinical date 4510. The first trial, targeted for end-2026, has already slipped from end-2025 8.
The tell is the option
For Merck holders the cost is an undisclosed line beside an in-house discovery organization; for Alphabet holders the payback on a named AI asset arrives as partner fees and royalties, years before any approved medicine. The number to watch is the one MSD did not disclose, and the move is the one Isomorphic now controls: if it co-funds an MSD trial, the $5 billion 4 stops being a research subsidy and starts buying royalty streams.
Get Deals by email, free
The acquisitions, rounds and contracts that move AI money. In our daily email, every weekday.






Reader comments
0 comments